D3-CAN-301

D3-CAN-301 is a small molecule cannabinoid derivative being developed by Octavian Therapeutics for the treatment of pain. In-licensed from Canopy Growth Corporation, the drug targets the endocannabinoid system (ECS), a complex cell-signaling system involved in regulating a variety of physiological functions including pain sensation, mood, and immune response. As a cannabinoid derivative, D3-CAN-301 is designed to modulate ECS receptors, such as CB1 and CB2, to provide therapeutic relief for chronic or inflammatory pain conditions. The program is part of Octavian's broader pipeline focused on leveraging cannabinoid science for medical applications, particularly in areas where traditional analgesics may be insufficient.

Other names

D3-CAN-301D-3-CAN-301D 3-CAN-301